<DOC>
	<DOCNO>NCT02293460</DOCNO>
	<brief_summary>Primary objective : To assess efficacy I10E improve disability patient CIDP . Secondary objective : To assess safety I10E patient CIDP .</brief_summary>
	<brief_title>Efficacy Safety Study I10E Treatment Patients With CIDP</brief_title>
	<detailed_description />
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<criteria>1 . Male female patient age 18 year 2 . Definite probable CIDP accord European Federation Neurological Societies ( EFNS ) /Peripheral Nerve Society ( PNS ) guideline 2010 clinical neurophysiological criterion Pure motor CIDP , provide diagnosis multifocal motor neuropathy rule CIDP associate monoclonal gammopathy undetermined significance ( MGUS ) , provide antiMAG antibody titer low use technique 's negativity threshold ( 1000 BTU Bühlmann ELISA technique ) LewisSumner syndrome 3 . Score least 2 adjusted INCAT disability scale 4 . Patient either : 1. never previously treat Ig ( Ignaive patient ) Or 2. previously treat Ig clinical relapse follow treatment withdrawal . In latter case , last Ig course shall administer less 3 month prior screen 1 . History IgA deficiency , unless absence antiIgA antibody document 2 . History cardiac insufficiency ( New York Heart Association [ NYHA ] III/IV ) , uncontrolled cardiac arrhythmia , unstable ischemic heart disease , uncontrolled hypertension 3 . History venous thromboembolic disease , myocardial infarction , cerebrovascular accident 4 . Risk factor blood hyperviscosity cryoglobulinemia haematologic malignancy monoclonal gammopathy 5 . Body mass Index ( BMI ) ≥40 kg/m² 6 . Glomerular filtration rate &lt; 80 mL/min/1.73m² measure accord Modified Diet Renal Disease ( MDRD ) calculation 7 . Any ongoing disease may cause chronic peripheral neuropathy , toxin exposure , dietary deficiency , uncontrolled diabetes , hyperthyroidism , cancer , systemic lupus erythematosus connective tissue disease , infection HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) , Lyme disease , multiple myeloma , Waldenström 's macroglobulinaemia , amyloid , hereditary neuropathy 8 . Woman positive result urine pregnancy test breastfeed woman woman childbearing potential without effective contraception . 9 . Any serious medical condition would interfere clinical assessment CIDP use I10E prevent patient comply protocol requirement 10 . Increasing dosage introduction corticotherapy within last 3 month prior screen , oral systemic corticosteroid dose high 10 mg daily prednisolone equivalent . Topical corticosteroid permit 11 . Treatment within 12 month prior screen immunomodulatory immunosuppressant agent ( include limit cyclophosphamide , cyclosporine , interferonalfa , interferonbeta1a , antiCD20 , alemtuzumab , aziathioprine , etanercept , mycophenolate mofetil , methotrexate haemopoetic stem cell transplantation ) 12 . Plasma exchange , blood product derivative administer within last 3 month prior screen 13 . Administration another investigational product within last month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Disimmune disease</keyword>
	<keyword>Neurology Chronic disease</keyword>
	<keyword>Rare disease</keyword>
</DOC>